Dynavax Technologies (NASDAQ: DVAX) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.
Institutional and Insider Ownership
77.6% of Dynavax Technologies shares are held by institutional investors. Comparatively, 86.6% of Sarepta Therapeutics shares are held by institutional investors. 3.5% of Dynavax Technologies shares are held by company insiders. Comparatively, 7.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Dynavax Technologies and Sarepta Therapeutics’ revenue, earnings per share and valuation.
||Earnings Per Share
Sarepta Therapeutics has higher revenue and earnings than Dynavax Technologies. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.
This table compares Dynavax Technologies and Sarepta Therapeutics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Risk & Volatility
Dynavax Technologies has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.
This is a summary of current ratings and price targets for Dynavax Technologies and Sarepta Therapeutics, as provided by MarketBeat.
||Strong Buy Ratings
Dynavax Technologies presently has a consensus target price of $27.40, suggesting a potential upside of 69.66%. Sarepta Therapeutics has a consensus target price of $95.48, suggesting a potential downside of 6.66%. Given Dynavax Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe Dynavax Technologies is more favorable than Sarepta Therapeutics.
Sarepta Therapeutics beats Dynavax Technologies on 10 of the 14 factors compared between the two stocks.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.